Alzamend Change To Liabilities from 2010 to 2025
| ALZN Stock | USD 0.89 0.21 30.88% |
Check Alzamend Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alzamend Neuro's main balance sheet or income statement drivers, such as , as well as many indicators such as . Alzamend financial statements analysis is a perfect complement when working with Alzamend Neuro Valuation or Volatility modules.
Alzamend |
About Alzamend Neuro Financial Statements
Alzamend Neuro investors utilize fundamental indicators, such as Change To Liabilities, to predict how Alzamend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Alzamend Neuro operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Check out the analysis of Alzamend Neuro Correlation against competitors. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.